Phase i and II metabolism and MRP2-mediated export of bosentan in a MDCKII-OATP1B1-CYP3A4-UGT1A1-MRP2 quadruple-transfected cell line

British Journal of Pharmacology

Volumn 169, Issue 1, 2013, Pages 21-33

  Fahrmayr, C ^a   Konig J ^a   Auge, D ^a   Mieth, M ^a   Munch K ^a   Segrestaa, J ^b   Pfeifer, T ^b   Treiber, A ^b   Fromm, M F ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b ACTELION PHARMACEUTICALS LTD   (Switzerland)

Author keywords

bosentan; CYP3A4; drug metabolism; drug transport; MDCKII; MRP2; OATP1B1; quadruple transfected cells; UGT1A1

Indexed keywords

BOSENTAN; CYTOCHROME P450 3A4; DRUG METABOLITE; GLUCURONOSYLTRANSFERASE 1A1; MULTIDRUG RESISTANCE PROTEIN 2; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTING POLYPEPTIDE 1B1; RO 478634; RO 484033; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL COMPARTMENTALIZATION; CELL LINE; CELL TRANSPORT; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG DETERMINATION; DRUG METABOLISM; DRUG TRANSPORT; GENETIC TRANSFECTION; IN VITRO STUDY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BIOLOGICAL TRANSPORT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, LIQUID; CYTOCHROME P-450 CYP3A; DOGS; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HUMANS; MADIN DARBY CANINE KIDNEY CELLS; MASS SPECTROMETRY; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; ORGANIC ANION TRANSPORTERS; PYRIMIDINES; RECEPTORS, ENDOTHELIN; SULFONAMIDES; TRANSFECTION;

EID: 84876230615     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12126     Document Type: Article

References (48)

1. Artursson P, Karlsson J, (1991). Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem Biophys Res Commun 175: 880-885.
2. van Aubel RA, Koenderink JB, Peters JG, Van Os CH, Russel FG, (1999). Mechanisms and interaction of vinblastine and reduced glutathione transport in membrane vesicles by the rabbit multidrug resistance protein Mrp2 expressed in insect cells. Mol Pharmacol 56: 714-719.
3. Clozel M, Breu V, Gray GA, Kalina B, Loffler BM, Burri K, et al. (1994). Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J Pharmacol Exp Ther 270: 228-235.
4. Cole SP, Deeley RG, (1998). Multidrug resistance mediated by the ATP-binding cassette transporter protein MRP. Bioessays 20: 931-940.
5. Cui Y, König J, Buchholz JK, Spring H, Leier I, Keppler D, (1999). Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol Pharmacol 55: 929-937.
6. Cui Y, König J, Keppler D, (2001). Vectorial transport by double-transfected cells expressing the human uptake transporter SLC21A8 and the apical export pump ABCC2. Mol Pharmacol 60: 934-943.
7. Dudka J, Jodynis-Liebert J, Korobowicz E, Burdan F, Korobowicz A, Szumilo J, et al. (2005). Activity of NADPH-cytochrome P-450 reductase of the human heart, liver and lungs in the presence of (-)-epigallocatechin gallate, quercetin and resveratrol: an in vitro study. Basic Clin Pharmacol Toxicol 97: 74-79.
8. Evers R, de Haas M, Sparidans R, Beijnen J, Wielinga PR, Lankelma J, et al. (2000). Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export. Br J Cancer 83: 375-383.
9. Fahrmayr C, König J, Auge D, Mieth M, Fromm MF, (2012). Identification of drugs and drug metabolites as substrates of multidrug resistance protein 2 (MRP2) using triple-transfected MDCK-OATP1B1-UGT1A1-MRP2 cells. Br J Pharmacol 165: 1836-1847.
10. Fattinger K, Funk C, Pantze M, Weber C, Reichen J, Stieger B, et al. (2001). The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin Pharmacol Ther 69: 223-231.
11. Fehrenbach T, Cui Y, Faulstich H, Keppler D, (2003). Characterization of the transport of the bicyclic peptide phalloidin by human hepatic transport proteins. Naunyn Schmiedebergs Arch Pharmacol 368: 415-420.
12. Fouassier L, Kinnman N, Lefevre G, Lasnier E, Rey C, Poupon R, et al. (2002). Contribution of mrp2 in alterations of canalicular bile formation by the endothelin antagonist bosentan. J Hepatol 37: 184-191.
13. Funk C, (2008). The role of hepatic transporters in drug elimination. Expert Opin Drug Metab Toxicol 4: 363-379.
14. van Giersbergen PL, Treiber A, Clozel M, Bodin F, Dingemanse J, (2002). In vivo and in vitro studies exploring the pharmacokinetic interaction between bosentan, a dual endothelin receptor antagonist, and glyburide. Clin Pharmacol Ther 71: 253-262.
15. van Giersbergen PL, Treiber A, Schneiter R, Dietrich H, Dingemanse J, (2007). Inhibitory and inductive effects of rifampin on the pharmacokinetics of bosentan in healthy subjects. Clin Pharmacol Ther 81: 414-419.
16. Glaeser H, Drescher S, van der, Kuip H, Behrens C, Geick A, Burk O, et al. (2002). Shed human enterocytes as a tool for the study of expression and function of intestinal drug-metabolizing enzymes and transporters. Clin Pharmacol Ther 71: 131-140.
17. Gomes AM, Winter S, Klein K, Turpeinen M, Schaeffeler E, Schwab M, et al. (2009). Pharmacogenomics of human liver cytochrome P450 oxidoreductase: multifactorial analysis and impact on microsomal drug oxidation. Pharmacogenomics 10: 579-599.
18. Hartman JC, Brouwer K, Mandagere A, Melvin L, Gorczynski R, (2010). Evaluation of the endothelin receptor antagonists ambrisentan, darusentan, bosentan, and sitaxsentan as substrates and inhibitors of hepatobiliary transporters in sandwich-cultured human hepatocytes. Can J Physiol Pharmacol 88: 682-691.
19. Hirouchi M, Kusuhara H, Onuki R, Ogilvie BW, Parkinson A, Sugiyama Y, (2009). Construction of triple-transfected cells [organic anion-transporting polypeptide (OATP) 1B1/multidrug resistance-associated protein (MRP) 2/MRP3 and OATP1B1/MRP2/MRP4] for analysis of the sinusoidal function of MRP3 and MRP4. Drug Metab Dispos 37: 2103-2111.
20. Ho RH, Kim RB, (2005). Transporters and drug therapy: implications for drug disposition and disease. Clin Pharmacol Ther 78: 260-277.
21. Ishiguro N, Maeda K, Saito A, Kishimoto W, Matsushima S, Ebner T, et al. (2008). Establishment of a set of double transfectants coexpressing organic anion transporting polypeptide 1B3 and hepatic efflux transporters for the characterization of the hepatobiliary transport of telmisartan acylglucuronide. Drug Metab Dispos 36: 796-805.
22. Jedlitschky G, Leier I, Buchholz U, Hummel-Eisenbeiss J, Burchell B, Keppler D, (1997). ATP-dependent transport of bilirubin glucuronides by the multidrug resistance protein MRP1 and its hepatocyte canalicular isoform MRP2. Biochem J 327 (Pt 1): 305-310.
23. Jedlitschky G, Hoffmann U, Kroemer HK, (2006). Structure and function of the MRP2 (ABCC2) protein and its role in drug disposition. Expert Opin Drug Metab Toxicol 2: 351-366.
24. Keppler D, Kartenbeck J, (1996). The canalicular conjugate export pump encoded by the cmrp/cmoat gene. Prog Liver Dis 14: 55-67.
25. König J, (2011). Uptake transporters of the human OATP family: molecular characteristics, substrates, their role in drug-drug interactions, and functional consequences of polymorphisms. In:, Fromm MF, Kim RB, (eds). Drug Transporters. Handbook of Experimental Pharmacology 201. Springer-Verlag: Berlin Heidelberg, pp. 1-28.
26. König J, Cui Y, Nies AT, Keppler D, (2000). A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. Am J Physiol Gastrointest Liver Physiol 278: G156-G164.
27. König J, Zolk O, Singer K, Hoffmann C, Fromm MF, (2011). Double-transfected MDCK cells expressing human OCT1/MATE1 or OCT2/MATE1: determinants of uptake and transcellular translocation of organic cations. Br J Pharmacol 163: 546-555.
28. Kopplow K, Letschert K, König J, Walter B, Keppler D, (2005). Human hepatobiliary transport of organic anions analyzed by quadruple-transfected cells. Mol Pharmacol 68: 1031-1038.
29. Loe DW, Deeley RG, Cole SP, (1998). Characterization of vincristine transport by the M(r) 190 000 multidrug resistance protein (MRP): evidence for cotransport with reduced glutathione. Cancer Res 58: 5130-5136.
30. Mandery K, Bujok K, Schmidt I, Wex T, Treiber G, Malfertheiner P, et al. (2010). Influence of cyclooxygenase inhibitors on the function of the prostaglandin transporter organic anion-transporting polypeptide 2A1 expressed in human gastroduodenal mucosa. J Pharmacol Exp Ther 332: 345-351.
31. Mano Y, Usui T, Kamimura H, (2007). Effects of bosentan, an endothelin receptor antagonist, on bile salt export pump and multidrug resistance- associated protein 2. Biopharm Drug Dispos 28: 13-18.
32. Nies AT, Herrmann E, Brom M, Keppler D, (2008). Vectorial transport of the plant alkaloid berberine by double-transfected cells expressing the human organic cation transporter 1 (OCT1, SLC22A1) and the efflux pump MDR1 P-glycoprotein (ABCB1). Naunyn Schmiedebergs Arch Pharmacol 376: 449-461.
33. Patki KC, Von Moltke LL, Greenblatt DJ, (2003). In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5. Drug Metab Dispos 31: 938-944.
34. Rappa G, Lorico A, Flavell RA, Sartorelli AC, (1997). Evidence that the multidrug resistance protein (MRP) functions as a co-transporter of glutathione and natural product toxins. Cancer Res 57: 5232-5237.
35. Rius M, Hummel-Eisenbeiss J, Hofmann AF, Keppler D, (2006). Substrate specificity of human ABCC4 (MRP4)-mediated cotransport of bile acids and reduced glutathione. Am J Physiol Gastrointest Liver Physiol 290: G640-G649.
36. Seithel A, Eberl S, Singer K, Auge D, Heinkele G, Wolf NB, et al. (2007). The influence of macrolide antibiotics on the uptake of organic anions and drugs mediated by OATP1B1 and OATP1B3. Drug Metab Dispos 35: 779-786.
37. Shen G, Yao M, Fura A, Zhu M, (2009). In vitro metabolite identification and cytochrome P450 reaction phenotyping of bosentan, a dual endothelin receptor antagonist. AAPS J 11 (S2): 001636 (abstract).
38. Swift B, Pfeifer ND, Brouwer KL, (2010). Sandwich-cultured hepatocytes: an in vitro model to evaluate hepatobiliary transporter-based drug interactions and hepatotoxicity. Drug Metab Rev 42: 446-471.
39. Tamura S, Korzekwa KR, Kimura S, Gelboin HV, Gonzalez FJ, (1992). Baculovirus-mediated expression and functional characterization of human NADPH-P450 oxidoreductase. Arch Biochem Biophys 293: 219-223.
40. Thorin E, Clozel M, (2010). The cardiovascular physiology and pharmacology of endothelin-1. Adv Pharmacol 60: 1-26.
41. Treiber A, Schneiter R, Delahaye S, Clozel M, (2004). Inhibition of organic anion transporting polypeptide-mediated hepatic uptake is the major determinant in the pharmacokinetic interaction between bosentan and cyclosporin A in the rat. J Pharmacol Exp Ther 308: 1121-1129.
42. Treiber A, Schneiter R, Hausler S, Stieger B, (2007). Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metab Dispos 35: 1400-1407.
43. Vermilion JL, Coon MJ, (1978). Purified liver microsomal NADPH-cytochrome P-450 reductase. Spectral characterization of oxidation-reduction states. J Biol Chem 253: 2694-2704.
44. Weber C, Schmitt R, Birnboeck H, Hopfgartner G, van, Marle SP, Peeters PA, et al. (1996). Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects. Clin Pharmacol Ther 60: 124-137.
45. Weber C, Banken L, Birnboeck H, Nave S, Schulz R, (1999a). The effect of bosentan on the pharmacokinetics of digoxin in healthy male subjects. Br J Clin Pharmacol 47: 701-706.
46. Weber C, Gasser R, Hopfgartner G, (1999b). Absorption, excretion, and metabolism of the endothelin receptor antagonist bosentan in healthy male subjects. Drug Metab Dispos 27: 810-815.
47. Weber C, Schmitt R, Birnboeck H, Hopfgartner G, Eggers H, Meyer J, et al. (1999c). Multiple-dose pharmacokinetics, safety, and tolerability of bosentan, an endothelin receptor antagonist, in healthy male volunteers. J Clin Pharmacol 39: 703-714.
48. Zolk O, Fromm MF, (2011). Transporter-mediated drug uptake and efflux: important determinants of adverse drug reactions. Clin Pharmacol Ther 89: 798-805.